Cite
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
MLA
Bottomley, Andrew, et al. “Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG/KEYNOTE-054): Health-Related Quality-of-Life Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial.” The Lancet. Oncology, vol. 22, no. 5, May 2021, pp. 655–64. EBSCOhost, https://doi.org/10.1016/S1470-2045(21)00081-4.
APA
Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., … Eggermont, A. M. M. (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology, 22(5), 655–664. https://doi.org/10.1016/S1470-2045(21)00081-4
Chicago
Bottomley, Andrew, Corneel Coens, Justyna Mierzynska, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, et al. 2021. “Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG/KEYNOTE-054): Health-Related Quality-of-Life Results from a Double-Blind, Randomised, Controlled, Phase 3 Trial.” The Lancet. Oncology 22 (5): 655–64. doi:10.1016/S1470-2045(21)00081-4.